Nanomaterials for radiotherapeutics-based multimodal synergistic cancer therapy

Yang, Xi; Gao, Ling; Guo, Qing; Li, Yongjiang; Ma, Yue; Yang, Ju; Gong, Changyang; Yi, Cheng

doi:10.1007/s12274-020-2722-z

Cited by 50 publications

(36 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 148 ] Utilizing the complementary reinforcement advantages of synergistic treatment, the optimal treatment efficacy could be realized at considerably decreased doses of the nanotherapeutic agent administered, thereby helping minimize the side effects. [ 149 ] Compared with ECDT‐based bimodal therapy, the treatment efficacy of ECDT‐based trimodal therapy can be dramatically improved via the synergistic reinforcement interactions between CDT and two other therapies. Meanwhile, the additional anticancer‐treatment efficacy of ECDT‐based trimodal therapy originates from the interpromotion of the combined two types of therapies.…”

Section: Enhanced Chemodynamic Therapy‐based Multimodal Synergistic Therapymentioning

confidence: 99%

Manipulating Intratumoral Fenton Chemistry for Enhanced Chemodynamic and Chemodynamic‐Synergized Multimodal Therapy

et al. 2021

View full text Add to dashboard Cite

Chemodynamic therapy (CDT) uses the tumor microenvironment‐assisted intratumoral Fenton reaction for generating highly toxic hydroxyl free radicals (•OH) to achieve selective tumor treatment. However, the limited intratumoral Fenton reaction efficiency restricts the therapeutic efficacy of CDT. Recent years have witnessed the impressive development of various strategies to increase the efficiency of intratumoral Fenton reaction. The introduction of these reinforcement strategies can dramatically improve the treatment efficiency of CDT and further promote the development of enhanced CDT (ECDT)‐based multimodal anticancer treatments. In this review, the authors systematically introduce these reinforcement strategies, from their basic working principles, reinforcement mechanisms to their representative clinical applications. Then, ECDT‐based multimodal anticancer therapy is discussed, including how to integrate these emerging Fenton reinforcement strategies for accelerating the development of multimodal anticancer therapy, as well as the synergistic mechanisms of ECDT and other treatment methods. Eventually, future direction and challenges of ECDT and ECDT‐based multimodal synergistic therapies are elaborated, highlighting the key scientific problems and unsolved technical bottlenecks to facilitate clinical translation.

show abstract

Section: Enhanced Chemodynamic Therapy‐based Multimodal Synergistic Therapymentioning

confidence: 99%

Manipulating Intratumoral Fenton Chemistry for Enhanced Chemodynamic and Chemodynamic‐Synergized Multimodal Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The generated electrons scintillate/excite multiple anthracene-based optical emitters in the MOF through inelastic scattering, leading to efficient generation of detectable photons in the visible spectrum. Most importantly, NMOFs have the ability to preferentially deposit in tumors by enhancing permeability and retention (EPR) effect ( Yang et al, 2020 ). In particular, the integration of photosensitizer to NMOFs not only addresses the limitations of photosensitizers, including aggregation, self-quenching, and uncontrollable in vivo but also improves loading efficiency, stability, and reduces cytotoxicity.…”

Section: Nanomedicine Applications Of Nanoscale Metal–organic Frameworkmentioning

confidence: 99%

Nanoscale Metal−Organic Frameworks and Their Nanomedicine Applications

Zhao

Zhang

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

Abundant connectivity among organic ligands and inorganic metal ions makes the physical and chemical characters of metal-organic frameworks (MOFs) could be precisely devised and modulated for specific applications. Especially nanoscale MOFs (NMOFs), a unique family of hybrid nanomaterials, with merits of holding the nature as the mainstay MOFs and demonstrating particle size in nanoscale range which enable them prospect platform in clinic. Adjustability of composition and structure allows NMOFs with different constituents, shapes, and characteristics. Oriented frameworks and highly porous provide enough space for packing therapeutic cargoes and various imaging agents efficiently. Moreover, the relatively labile metal-ligand bonds make NMOFs biodegradable in nature. So far, as a significant class of biomedically relevant nanomaterials, NMOFs have been explored as drug carriers, therapeutic preparation, and biosensing and imaging preparation owing to their high porosity, multifunctionality, and biocompatibility. This review provides up-to-date developments of NMOFs in biomedical applications with emphasis on size control, synthetic approaches, and surfaces functionalization as well as stability, degradation, and toxicity. The outlooks and several crucial issues of this area are also discussed, with the expectation that it may help arouse widespread attention on exploring NMOFs in potential clinical applications.

show abstract

“…Radioisotope therapy (RIT) and internal‐external beam RT (EBRT) have been extensively adopted in clinical cancer treatment (DuRoss, Neufeld, Rana, Thomas Jr., & Sun, 2019; Yang et al, 2020; Yao et al, 2018; Yu et al, 2019). Despite the satisfactory therapeutic efficacy of RT, it still has intrinsic dilemmas (Liu, Pan, & Liu, 2020; Pan et al, 2020).…”

Section: Energy‐converting Biomaterials For Cancer Therapymentioning

confidence: 99%

Energy‐converting biomaterials for cancer therapy: Category, efficiency, and biosafety

Dong

Sun

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Energy‐converting biomaterials (ECBs)‐mediated cancer‐therapeutic modalities have been extensively explored, which have achieved remarkable benefits to overwhelm the obstacles of traditional cancer‐treatment modalities. Energy‐driven cancer‐therapeutic modalities feature their distinctive merits, including noninvasiveness, low mammalian toxicity, adequate therapeutic outcome, and optimistical synergistic therapeutics. In this advanced review, the prevailing mainstream ECBs can be divided into two sections: Reactive oxygen species (ROS)‐associated energy‐converting biomaterials (ROS‐ECBs) and hyperthermia‐related energy‐converting biomaterials (H‐ECBs). On the one hand, ROS‐ECBs can transfer exogenous or endogenous energy (such as light, radiation, ultrasound, or chemical) to generate and release highly toxic ROS for inducing tumor cell apoptosis/necrosis, including photo‐driven ROS‐ECBs for photodynamic therapy, radiation‐driven ROS‐ECBs for radiotherapy, ultrasound‐driven ROS‐ECBs for sonodynamic therapy, and chemical‐driven ROS‐ECBs for chemodynamic therapy. On the other hand, H‐ECBs could translate the external energy (such as light and magnetic) into heat for killing tumor cells, including photo‐converted H‐ECBs for photothermal therapy and magnetic‐converted H‐ECBs for magnetic hyperthermia therapy. Additionally, the biosafety issues of ECBs are expounded preliminarily, guaranteeing the ever‐stringent requirements of clinical translation. Finally, we discussed the prospects and facing challenges for constructing the new‐generation ECBs for establishing intriguing energy‐driven cancer‐therapeutic modalities. This article is categorized under: Nanotechnology Approaches to Biology >Nanoscale Systems in Biology

show abstract

Nanomaterials for radiotherapeutics-based multimodal synergistic cancer therapy

Cited by 50 publications

References 140 publications

Manipulating Intratumoral Fenton Chemistry for Enhanced Chemodynamic and Chemodynamic‐Synergized Multimodal Therapy

Manipulating Intratumoral Fenton Chemistry for Enhanced Chemodynamic and Chemodynamic‐Synergized Multimodal Therapy

Nanoscale Metal−Organic Frameworks and Their Nanomedicine Applications

Energy‐converting biomaterials for cancer therapy: Category, efficiency, and biosafety

Contact Info

Product

Resources

About